Outcomes of a Pharmacist-managed Clinic for Underserved Persons with Unmanaged Type 2 Diabetes Mellitus

Overview

Journal J Pharm Pract Res

Specialty Pharmacology

Date 2023 Feb 23

PMID 36815097

Authors

Ashley L Lefebvre

Andrew R Zullo

Ruth Dapaah-Afriyie

Christine M Collins

Khaled A Elsaid

Affiliations

Soon will be listed here.

Abstract

Background: A multidisciplinary approach is recommended for the management of type 2 diabetes mellitus (DM).

Aim: To evaluate the impact of a pharmacist intervention on haemoglobin A1c (HbA), systolic blood pressure (SBP), diastolic blood pressure (DBP), and diabetes-related hospitalisations in an underserved cohort with unmanaged type 2 DM.

Methods: This analysis was a retrospective cohort study. Criteria for inclusion were persons with unmanaged type 2 DM defined as HbA values ≥8% at time of enrolment, ≥18 years old, and enrolment in a pharmacist-managed clinic for ≥12 months. Pre- and post-intervention differences in HbA, SBP and DBP values were assessed using repeated measures analysis of variance (ANOVA). The risk of diabetes-related hospitalisations was estimated during the 12 months prior and during the 12 months post-intervention, and the relative risk (RR) was calculated.

Results: Mean HbA values at 3, 6 and 12 months post-intervention were lower than baseline values (p < 0.05). There was no significant difference in mean HbA values at 6 or 12 months compared to 3 months post intervention. Mean SBP values at 3, 6 and 12 months were lower than baseline (p < 0.05). Likewise, mean DBP values at 6 and 12 months were lower than baseline (p < 0.05). The estimated RR of diabetes-related hospitalisations was 0.40 (95% CI: 0.20-0.83; p = 0.013).

Conclusion: Enrolment in a pharmacist-managed diabetes program was associated with a significant reduction in HbA1c, SBP and DBP and reduction in risk of diabetes-related hospitalisations in an underserved cohort of patients with diabetes over a 12-month period.

Citing Articles

Implementation of a Pharmacist-Led Diabetes Management Protocol.

Al-Omar L, Anderson S, Cizmic A, Vlasimsky T Am Health Drug Benefits. 2019; 12(1):14-20.

PMID: 30972149 PMC: 6404803.

References

Kiel P, McCord A . Pharmacist impact on clinical outcomes in a diabetes disease management program via collaborative practice. Ann Pharmacother. 2005; 39(11):1828-32. DOI: 10.1345/aph.1G356. View

Wubben D, Vivian E . Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy. 2008; 28(4):421-36. DOI: 10.1592/phco.28.4.421. View

Finley P, Rens H, Pont J, Gess S, Louie C, Bull S . Impact of a collaborative pharmacy practice model on the treatment of depression in primary care. Am J Health Syst Pharm. 2002; 59(16):1518-26. DOI: 10.1093/ajhp/59.16.1518. View

McAdam-Marx C, Dahal A, Jennings B, Singhal M, Gunning K . The effect of a diabetes collaborative care management program on clinical and economic outcomes in patients with type 2 diabetes. J Manag Care Spec Pharm. 2015; 21(6):452-68. PMC: 10401972. DOI: 10.18553/jmcp.2015.21.6.452. View

Gaster B, Hirsch I . The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med. 1998; 158(2):134-40. DOI: 10.1001/archinte.158.2.134. View

Morello C, Zadvorny E, Cording M, Suemoto R, Skog J, Harari A . Development and clinical outcomes of pharmacist-managed diabetes care clinics. Am J Health Syst Pharm. 2006; 63(14):1325-31. DOI: 10.2146/ajhp050430. View

Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo Jr J . Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42(6):1206-52. DOI: 10.1161/01.HYP.0000107251.49515.c2. View

Cranor C, Bunting B, Christensen D . The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash). 2003; 43(2):173-84. DOI: 10.1331/108658003321480713. View

. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016; 387(10027):1513-1530. PMC: 5081106. DOI: 10.1016/S0140-6736(16)00618-8. View

10.

Rothman R, Malone R, Bryant B, Horlen C, Pignone M . Pharmacist-led, primary care-based disease management improves hemoglobin A1c in high-risk patients with diabetes. Am J Med Qual. 2003; 18(2):51-8. DOI: 10.1177/106286060301800202. View

11.

Lago R, Singh P, Nesto R . Diabetes and hypertension. Nat Clin Pract Endocrinol Metab. 2007; 3(10):667. DOI: 10.1038/ncpendmet0638. View

12.

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

13.

. American Diabetes Association: clinical practice recommendations 1997. Diabetes Care. 1997; 20 Suppl 1:S1-70. View

14.

Stolar M . Glycemic control and complications in type 2 diabetes mellitus. Am J Med. 2010; 123(3 Suppl):S3-11. DOI: 10.1016/j.amjmed.2009.12.004. View

15.

Vijan S, Hofer T, Hayward R . Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med. 1998; 127(9):788-95. DOI: 10.7326/0003-4819-127-9-199711010-00003. View

16.

Machado M, Bajcar J, Guzzo G, Einarson T . Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother. 2007; 41(10):1569-82. DOI: 10.1345/aph.1K151. View

17.

Iyer R, Coderre P, McKelvey T, Cooper J, Berger J, Moore E . An employer-based, pharmacist intervention model for patients with type 2 diabetes. Am J Health Syst Pharm. 2010; 67(4):312-6. DOI: 10.2146/ajhp090047. View

18.

Anaya J, Rivera J, Lawson K, Garcia J, Luna Jr J, Ortiz M . Evaluation of pharmacist-managed diabetes mellitus under a collaborative drug therapy agreement. Am J Health Syst Pharm. 2008; 65(19):1841-5. DOI: 10.2146/ajhp070568. View

19.

Sowers J, Epstein M . Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension. 1995; 26(6 Pt 1):869-79. DOI: 10.1161/01.hyp.26.6.869. View

20.

Chung N, Rascati K, Lopez D, Jokerst J, Garza A . Impact of a clinical pharmacy program on changes in hemoglobin A1c, diabetes-related hospitalizations, and diabetes-related emergency department visits for patients with diabetes in an underserved population. J Manag Care Spec Pharm. 2014; 20(9):914-9. PMC: 10437343. DOI: 10.18553/jmcp.2014.20.9.914. View